a user-friendly procedure that analyses genomic, clinical and demographic data to generate a personalized report with statistical analysis on the efficacy of antidepressants and their side effects

Project Information

Predictix Antidepres

Grant agreement ID: 832230

DOI

10.3030/832230

Project closed

EC signature date 4 December 2018

Start date 1 November 2018

End date 28 February 2019

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

TALIAZ LTD
Israel

Periodic Reporting for period 1 - Predictix Antidepres (a user-friendly procedure that analyses genomic, clinical and demographic data to generate a personalized report with statistical analysis on the efficacy of antidepressants and their side effects)

Reporting period: 2018-11-01 to 2019-02-28

Summary of the context and overall objectives of the project

The total number of people living with depression in the world is 332 million. One in twenty people in Europe currently live with depression, and one in four will suffer a depressive episode at some point in their lives . Depression is one of the most disabling diseases, and causes a significant burden both to the individual and to society. Neuropsychiatric disorders, such as depression, account for the 26% of the burden of disease in the European Union (EU) countries. Antidepressants are a primary method for treatment of depression. Nevertheless, finding the right antidepressant turns into a trial-and-error process lasting months. As of today, there is no reliable system to help direct clinicians to the right antidepressant for each patient, resulting in only approximately 35% remission rates after the first prescription. Taliaz has developed the Predictix™, a decision support tool to help clinicians identify the right treatment to depression for each patient, helping them to beat depression sooner. Predictix™ is a software that employs user-friendly procedure that analyses genomic, clinical and demographic data to generate a personalized report with statistical analysis on the efficacy of antidepressants, their side effects and dosage. Predictix™ uses sophisticated AI-based algorithms, which can reach up to nearly 80% success in matching the depressed patient with his personalised treatment. The Predictix™ targets the need for personalized medicine and better informed clinical decisions in the psychiatry practice in general, and in the treatment of depressive disorders in particular.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

During Phase 1, Taliaz produced a work plan, detailing the main technical steps to make Predictix™ ready for market. Also during the Feasibility Study, the business viability has been evaluated by means of a detailed market analysis (size, barriers, customer segments, competitors) and preparing a commercialisation strategy and a detailed financial analysis to understand the expected financial performance. The results achieved during the project, confirming the products expected performance by all stakeholders will be communicated through a series of communication channels (online, events such as conferences, publications).

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

In this framework personalised medicine is the fastest, most economic and optimized solution to the depression treatment problem. Predictix™ will allow medical practitioners to have up-to-date and accurate knowledge on each case and improve the care that patient receives, with an economic revenue too. Taliaz’s mission is to set a new standard in personalized medicine improving quality of life for patients suffering from depression. Taliaz takes advantage of in-house expertise in genetics, data science and central nervous system related disease with the advancements in genetic sequencing and machine learning technologies, to develop leading personal medicine proprietary IP solutions for depression. Our vision is to use Predictix™ also as a decision support tool for common health concerns such as ADHD and Anxiety. The SME Instrument project now perfectly fits our strategy and vision by enabling a fast finalisation of the platform development and by providing us the resources necessary to demonstrate the benefits of Predictix™ through an international postmarketing surveillance study.

predictix.png